Reuters logo
BRIEF-Synthetic Biologics' SYN-004 achieves primary endpoint in phase 2B trial
January 5, 2017 / 12:25 PM / 9 months ago

BRIEF-Synthetic Biologics' SYN-004 achieves primary endpoint in phase 2B trial

Jan 5 (Reuters) - Synthetic Biologics Inc

* Synthetic biologics’ SYN-004 (ribaxamase) achieves primary endpoint in phase 2B trial for C. Difficile infection (CDI)

* Adverse events reported during thetrial were comparable between treatment and placebo arms

* Company expects to share additional results from these exploratory endpoints as they become available later this year

* Co is also continuing to prepare for initiation of pivotal phase 2B/3 clinical trials for SYN-010 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below